People | July 23, 2025
Biocon Biologics appoints Deepali Naair as Global Head - Brand & Corporate Communications
She was Group Chief Marketing Officer at CKA Birla Group in her last role
She was Group Chief Marketing Officer at CKA Birla Group in her last role
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
